The highly selective MAGL inhibitor, MJN110, displays neuroprotective effects in vitro, by reducing neuronal hyperexcitability and restoring dendritic arborization complexity, and in vivo, by mitigating Tat-induced neurocognitive alterations.31 These findings indicate that MAGL inhibitors represent a viable target for treating HAND. Here, MGLL is linked to HIV-associated neurocognitive disorder.